Kelli N Burger
Overview
Explore the profile of Kelli N Burger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
599
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Urquhart S, Pallipamu N, Voruganti H, Baraskar B, Muddaloor P, Sethi A, et al.
J Crohns Colitis
. 2025 Feb;
19(2).
PMID: 39901738
Background And Aims: Patients with inflammatory bowel disease (IBD) face increased risk of colorectal cancer (CRC). While the natural history of conventional dysplastic precursor lesions has been well-studied, the neoplastic...
2.
Witzig T, Taylor W, Mahoney D, Bamlet W, Foote P, Burger K, et al.
Am J Hematol
. 2024 Nov;
100(2):218-228.
PMID: 39564730
Lymphoma is one of the leading causes of cancer and cancer deaths and yet has not been amenable to population screening. The role of methylated DNA markers (MDMs) in the...
3.
Engels M, Berger C, Mahoney D, Hoogenboom S, Sarwal D, Klatte D, et al.
Clin Gastroenterol Hepatol
. 2024 Oct;
PMID: 39477082
Background And Aims: In previous studies, methylated DNA markers (MDMs) have been identified in pancreatic juice (PJ) for detecting pancreatic ductal adenocarcinoma (PDAC). In this prospective multicenter study, the sensitivity...
4.
Shah P, Taylor W, Negaard B, Gochanour B, Mahoney D, Then S, et al.
Life (Basel)
. 2024 Aug;
14(8).
PMID: 39202766
Introduction: Non-invasive assays are needed to better discriminate patients with prostate cancer (PCa) to avoid over-treatment of indolent disease. We analyzed 14 methylated DNA markers (MDMs) from urine samples of...
5.
Northrop-Albrecht E, Wu C, Berger C, Taylor W, Foote P, Doering K, et al.
PLoS One
. 2024 Aug;
19(8):e0308711.
PMID: 39146279
Regular screening for colorectal cancer (CRC) is critical for early detection and long-term survival. Despite the current screening options available and advancements in therapies there will be around 53,000 CRC...
6.
Majumder S, Halfdanarson T, Berger C, Foote P, Cao X, McGlinch M, et al.
Gastro Hep Adv
. 2024 Aug;
1(3):409-416.
PMID: 39131680
Background And Aims: Methylated DNA markers (MDMs) accurately identify several different cancer types, but there are limited data for pancreatic neuroendocrine tumors (pNETs). We aimed to identify MDM candidates in...
7.
Zhu M, Taylor W, Mahoney D, Then S, Berger C, Burger K, et al.
Cancers (Basel)
. 2023 Dec;
15(24).
PMID: 38136324
Background: Radiographic surveillance of colorectal cancer (CRC) after curative-intent therapy is costly and unreliable. Methylated DNA markers (MDMs) detected primary CRC and metastatic recurrence with high sensitivity and specificity in...
8.
Berger C, Taylor W, Mahoney D, Burger K, Doering K, Gonser A, et al.
JCO Precis Oncol
. 2023 Oct;
7:e2300389.
PMID: 37883729
Purpose: Surveillance after primary melanoma treatment aims to detect early signs of low-volume systemic disease. The current standard of care, surveillance imaging, is costly and difficult to access. We therefore...
9.
Ebner D, Burger K, Broderick B, Mahoney D, Kellogg T, Acosta A, et al.
Gastro Hep Adv
. 2023 Oct;
2(7):902-910.
PMID: 37876832
Background And Aims: Bariatric and metabolic surgery (BMS) may adversely affect noninvasive stool tests for colorectal cancer (CRC) screening through several mechanisms. Multitarget stool DNA (mt-sDNA) is approved for CRC...
10.
Bramblet R, Bakkum-Gamez J, Slettedahl S, Foote P, Taylor W, Berger C, et al.
Cancer Prev Res (Phila)
. 2023 Sep;
16(11):611-620.
PMID: 37728516
Prevention Relevance: Lynch syndrome (LS) markedly increases risks of colorectal and endometrial cancers. Early detection biomarkers for LS cancers could reduce the needs for invasive screening and surgery. Methylated DNA...